ClinicalTrials.gg
RecruitingNCT06304857PROTECTAAUpdated Dec 4, 2024

CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL

A Phase 3 interventional study of Dapagliflozin and Placebo in Breast Cancer and Heart Failure, sponsored by 4th Military Clinical Hospital with Polyclinic, Poland. Recruiting at 3 sites in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by 4th Military Clinical Hospital with Polyclinic, Poland · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 282 studies in Breast Neoplasms with a site in Poland — 33 open to participants now, 91 under way, 66 of them phase 3. Breast Neoplasms · Poland.

Planned enrollment
186th of 260
188 · median 450
Started
2024
with 10 others
Phase 3
154 of 282
21 open now
Primary completion
2026-12
later than 39 of 90 live
Registered
251st of 282
by date

Among the 282 studies in Breast Neoplasms with a site in Poland, this one is the 186th largest by planned enrollment of the 260 interventional ones that give a count, is one of 11 that started in 2024, is one of 154 in phase 3, reaches primary completion later than 39 of the 90 other live ones, and was the 251st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

33 of the 282 studies in Breast Neoplasms with a site in Poland are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 282 studies in Breast Neoplasms with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.

Read the detailed description

This is a multicentre, randomised, double-blind, placebo-controlled phase III study, evaluating the effect of dapagliflozin versus placebo on prevention of cardiotoxicity in breast cancer patients undergoing anthracycline-based chemotherapy.

03

Conditions studied

  • Breast Cancer
  • Heart Failure

Keywords

  • breast cancer
  • heart failure
  • ejection fraction
  • anthracyclines
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years and \< 80 years.
  • Diagnosis of invasive breast cancer [stage I-III] and planned anthracycline treatment within 60 days.
  • Signed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Urinary tract infection with the need for treatment with an antibiotic 48 hours before the scheduled start of anthracycline treatment.
  • Recognised heart failure or symptoms which, in the opinion of the investigator may be a symptom of undiagnosed heart failure.
  • \< 50% at the time of the screening.
  • Severe valvular heart disease.
  • A history of arrhythmia, including atrial fibrillation regardless of type (at discretion of the investigator).
  • A history of stroke.
  • Cardiomyopathy: congenital, post-inflammatory, toxic, infiltrative (e.g. amyloidosis, sarcoidosis, haemochromatosis), postnatal or hypertrophic.
  • Pulmonary hypertension.
  • Uncontrolled arterial pressure or systolic pressure \< 80 mmHg at screening (at the discretion of the investigator).
  • > 40 kg/m2.
  • Diagnosed type 1 or type 2 diabetes or fasting glucose ≥ 126 mg/dl or ≥ 6,5% (48 mmol/mol).
  • Pregnancy or breastfeeding.
  • Lack of compliance to use highly effective method of .
  • Expected or possible treatment with epirubicin or liposomal doxorubicin within 12 months.
  • Taking another study drug or drugs from the group of SGLT2 inhibitors up to 6 months before the screening visit.
  • Taking semaglutide, liraglutide and metformin during the 30 days preceding the screening visit.
  • \< 25 ml/min/1.73m2 according to CKD EPI.
  • \< 12 months or cancer disease stage IV according to the TNM classification.
  • or aspartate transaminase levels above 2.5 times the local norm.
  • Anemia with \< 9 g/dl.
  • Kidney failure > G2 (according to KDIGO classification).
  • Liver disorders, score > 4.
  • Known, active infections with , , , tuberculosis.
  • Any other condition which, in the opinion of the investigator, makes it impossible to fulfill the requirements for participation in this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
188 participants (estimated)

Study arms

  • Experimental
    Dapagliflozin

    Dapagliflozin 10 mg tablet orally once daily for 12 months

    Drug: Dapagliflozin

  • Placebo comparator
    Placebo

    Placebo tablet matching dapagliflozin orally once daily for 12 months

    Drug: Placebo

Interventions

  • 10 mg tablet q.d

    Also known as: Farxiga, Forxiga

  • DrugPlacebo

    tablet matching dapagliflozin 10 mg q.d

06

What researchers measure

Primary outcomes

  1. Primary efficacy composite endpoint (cancer therapeutics related cardiac dysfunction) at 12 months.

    Incidence of cancer therapeutics related cardiac dysfunction defined as: 1. the appearance of heart failure symptoms (NYHA class I-IV) due to an impairment of heart function or structure within 12 months; or 2. asymptomatic decrease in left ventricular ejection fraction \> 10% after 12 months; or 3. asymptomatic decrease in left ventricular ejection fraction \< 10% but up to 40-49% after 12 months; or 4. asymptomatic decrease in global left ventricular longitudinal strain \>15% after 12 months; or 5. asymptomatic increase in biomarkers (troponin I \> upper reference limit (99th centile) and increase of at least 30% from pre-treatment concentration or NTproBNP \> 125 pg/ml and increase of at least 30% from baseline) after 12 months.

    Time frame: 12 months

Secondary outcomes

  1. Secondary efficacy composite endpoint (cancer therapeutics related cardiac dysfunction) at 6 months.

    Incidence of cancer therapeutics related cardiac dysfunction defined as: 1. emergence of heart failure symptoms (NYHA class I-IV) due to impaired cardiac function or structure at 6 months; or 2. decrease LVEF \> 10% after 6 months; or 3. decrease LVEF \< 10% but to a value of 40-49% after 6 months; or 4. a decrease in global longitudinal strain of \> 15% after 6 months; or 5. asymptomatic increase in biomarkers (troponin I \> upper reference limit (99th centile) and an increase of at least 30% from pre-treatment concentration or NTproBNP \>125pg/ml and an increase of at least 30% from baseline) after 6 months.

    Time frame: 6 months

  2. Change in left ventricular ejection fraction at 6 and 12 months.

    Assessed by transthoracic echocardiography.

    Time frame: 6 and 12 months

  3. Change in left ventricular diastolic function at 6 and 12 months.

    Assessed as the ratio of E/E', i.e. maximum mitral annular inflow velocity during the rapid ventricular filling phase, to maximum mitral annular motion velocity by tissue Doppler during the rapid ventricular filling phase.

    Time frame: 6 and 12 months

  4. Change in Troponin I after 6 and 12 months.

    Secondary.

    Time frame: 6 and 12 months

  5. Change in NTproBNP levels at 6 and 12 months.

    Secondary.

    Time frame: 6 and 12 months

  6. Quality of life at 6 and 12 months assessed using the five-dimensional EQ-5D questionnaire.

    The EQ-5D questionnaire consists of two parts: descriptive one, which measures five dimensions of health (mobility, self care, usual activities, pain \& discomfort, anxiety \& depression) and EQ Visual Analogue Scale numbered from 0 to 100, where higher value indicate better self-reported health.

    Time frame: 6 and 12 months

  7. Occurrence of death from any cause.

    Secondary safety endpoint.

    Time frame: 13 months (additional 1 month of safety follow-up after end of treatment).

  8. Composite endpoint of cardiovascular events.

    Secondary safety endpoint. Occurrence of death from cardiovascular causes, nonfatal myocardial infarction, non-fatal stroke.

    Time frame: 13 months (additional 1 month of safety follow-up after end of treatment).

  9. Occurrence of death from any cardiovascular reasons.

    Secondary safety endpoint.

    Time frame: 13 months (additional 1 month of safety follow-up after end of treatment).

  10. Occurrence of non-fatal myocardial infarction.

    Secondary safety endpoint.

    Time frame: 13 months (additional 1 month of safety follow-up after end of treatment).

  11. Occurrence of non-fatal stroke.

    Secondary safety endpoint.

    Time frame: 13 months (additional 1 month of safety follow-up after end of treatment).

  12. Occurrence of hypoglycaemia.

    Secondary safety endpoint. Hypoglycaemia is defined as serum glucose level 3 mmol/l (\<54 mg/dl) with coexisting related clinical symptoms.

    Time frame: 13 months (additional 1 month of safety follow-up after end of treatment).

  13. Occurrence of ionic disorders.

    Secondary safety endpoint, defined as occurrence of: * Sodium plasma level of \>150 mmol/L * Potassium plasma level of \>6.0 mmol/L

    Time frame: 13 months (additional 1 month of safety follow-up after end of treatment).

  14. Occurrence of renal failure.

    Secondary safety endpoint. Defined as: * sustained (i.e. \>28 days) decline in eGFR ≥50% AND/OR * reaching end stage renal disease defined as: * sustained (i.e. \>28 days) eGFR \<15 mL/min/1.73 m2 * chronic dialysis treatment * receiving a renal transplant AND/OR * renal death

    Time frame: 13 months (additional 1 month of safety follow-up after end of treatment).

  15. Occurrence of hypersensitivity to investigated drug.

    Secondary safety endpoint. Any unexpected adverse drug reaction (UADR).

    Time frame: 13 months (additional 1 month of safety follow-up after end of treatment).

  16. Occurrence of allergic reactions.

    Secondary safety endpoint. Any hypersensitivity reaction with proven immunological pathomechanism (types I-IV according to Coombs and Gell).

    Time frame: 13 months (additional 1 month of safety follow-up after end of treatment).

  17. Occurrence of infection.

    Secondary safety endpoint. Any symptomatic infection (viral, bacterial or fungal).

    Time frame: 13 months (additional 1 month of safety follow-up after end of treatment).

07

Study locations

3 of 3 sites recruiting
  • 4th Military Clinical Hospital with Polyclinic
    Wrocław, Dolnośląskie 50-981, Poland
    Recruiting
  • Lower Silesian Centre for Oncology, Lung Diseases and Hematology
    Wrocław, Dolnośląskie 53-413, Poland
    Recruiting
    • Rafał Matkowski, PhD, MD · Contact
  • Military Medical Institute
    Warsaw, Mazowieckie 04-141, Poland
    Recruiting
    • Paweł Krzesiński, PhD, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 32 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2023
First posted
Mar 12, 2024
StartActual
Apr 15, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06304857
Lead sponsor
4th Military Clinical Hospital with Polyclinic, Poland
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Apr 15, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 4, 2024

Study contacts

Bartosz Krakowiak, PhD, MD
Contact
bkrakowiak@4wsk.pl
+48 261 660 234
Waldemar Banasiak, PhD, MD
principal investigator · 4th Military Clinical Hospital with Polyclinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion